Tom W J Huizinga

List of Publications by Year
in descending order

581	55,741	2322	1505
papers	citations	98 h-index	219 g-index

598	598	598	42301
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
4	Rheumatoid arthritis. Lancet, The, 2010, 376, 1094-1108.	13.7	2,712
5	Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014, 506, 376-381.	27.8	1,974
6	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
7	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 964-975.	0.9	1,429
8	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nature Genetics, 2010, 42, 508-514.	21.4	1,132
9	Transient expression of FOXP3 in human activated nonregulatory CD4⁺ T cells. European Journal of Immunology, 2007, 37, 129-138.	2.9	912
10	Genetic influence on cytokine production and fatal meningococcal disease. Lancet, The, 1997, 349, 170-173.	13.7	757
11	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nature Genetics, 2012, 44, 1336-1340.	21.4	558
12	Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis and Cartilage, 2012, 20, 1484-1499.	1.3	506
13	Refining the complex rheumatoid arthritis phenotype based on specificity of the HLAâ€“DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis and Rheumatism, 2005, 52, 3433-3438.	6.7	496
14	Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nature Genetics, 2008, 40, 1216-1223.	21.4	476
15	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17372-17377.	7.1	464
16	Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9465-9470.	7.1	458
17	Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Research and Therapy, 2005, 7, R949-58.	3.5	400
18	The Pi-linked receptor FcRIII is released on stimulation of neutrophils. Nature, 1988, 333, 667-669.	27.8	395

#	Article	IF	Citations
19	Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight-week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis and Rheumatism, 2001, 44, 1515-1524.	6.7	368
20	Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism, 2007, 56, 1424-1432.	6.7	363
21	Longâ€term impact of delay in assessment of patients with early arthritis. Arthritis and Rheumatism, 2010, 62, 3537-3546.	6.7	357
22	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.9	354
23	Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 Production and Enhance the Risk of Systemic Lupus Erythematosus. Journal of Immunology, 2001, 166, 3915-3922.	0.8	353
24	Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis. Journal of Biological Chemistry, 2003, 278, 40967-40972.	3.4	333
25	Association between weight or body mass index and hand osteoarthritis: a systematic review. Annals of the Rheumatic Diseases, 2010, 69, 761-765.	0.9	332
26	A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions. Arthritis and Rheumatism, 2007, 56, 433-440.	6.7	320
27	Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 2113-2121.	6.7	319
28	Meta-Analysis of Genome-Wide Association Studies in Celiac Disease and Rheumatoid Arthritis Identifies Fourteen Non-HLA Shared Loci. PLoS Genetics, 2011, 7, e1002004.	3.5	307
29	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nature Genetics, 2009, 41, 1313-1318.	21.4	306
30	Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Annals of the Rheumatic Diseases, 2011, 70, 60-67.	0.9	302
31	The HLAâ€“DRB1 shared epitope alleles are primarily a risk factor for antiâ€“cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 1117-1121.	6.7	294
32	Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1554-1561.	0.9	268
33	Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Annals of the Rheumatic Diseases, 2013, 72, 43-50.	0.9	259
34	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Annals of the Rheumatic Diseases, 2016, 75, 952-957.	0.9	258
35	Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Human Molecular Genetics, 2004, 13, 1755-1762.	2.9	249
36	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis and Rheumatism, 2010, 62, 2582-2591.	6.7	246

#	Article	IF	Citations
37	Predicting arthritis outcomes–what can be learned from the Leiden Early Arthritis Clinic?. Rheumatology, 2011, 50, 93-100.	1.9	240
38	A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis. PLoS Medicine, 2007, 4, e278.	8.4	232
39	Inflammation underlying cardiovascular mortality is a late consequence of evolutionary programming. FASEB Journal, 2004, 18, 1022-1024.	0.5	231
40	A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1765-1775.	6.7	225
41	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 234-241.	0.9	225
42	TNF-Î± promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. Journal of Neuroimmunology, 1997, 72, 149-153.	2.3	214
43	Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study. Arthritis and Rheumatology, 2015, 67, 1424-1437.	5.6	213
44	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the Rheumatic Diseases, 2010, 69, 638-643.	0.9	203
45	Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24â€…months, with a 12-month, double-blind treatment period. Annals of the Rheumatic Diseases, 2015, 74, 19-26.	0.9	201
46	Quantitative heritability of antiâ€“citrullinated protein antibodyâ€“positive and antiâ€“citrullinated protein antibodyâ€“negative rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 916-923.	6.7	200
47	Antibodies toPorphyromonas gingivalisAre Associated with Anticitrullinated Protein Antibodies in Patients with Rheumatoid Arthritis and Their Relatives. Journal of Rheumatology, 2010, 37, 1105-1112.	2.0	195
48	Prevalence of and predictive factors for sustained diseaseâ€modifying antirheumatic drugâ€“free remission in rheumatoid arthritis: Results from two large early arthritis cohorts. Arthritis and Rheumatism, 2009, 60, 2262-2271.	6.7	193
49	Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis and Rheumatism, 2006, 54, 1087-1095.	6.7	188
50	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 780-783.	0.9	185
51	The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis and Rheumatism, 2001, 44, 2525-2530.	6.7	184
52	Glycan profiling of antiâ€“citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis and Rheumatism, 2010, 62, 1620-1629.	6.7	183
53	The influence of ACPA status and characteristics on the course of RA. Nature Reviews Rheumatology, 2012, 8, 144-152.	8.0	173
54	Sarilumab, a fully human monoclonal antibody against IL-6RÎ± in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Annals of the Rheumatic Diseases, 2014, 73, 1626-1634.	0.9	173

#	Article	IF	Citations
55	Brief Report: Antiâ€“Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatism, 2013, 65, 911-915.	6.7	164
56	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. Nature Genetics, 2015, 47, 1085-1090.	21.4	164
57	An overview of autoantibodies in rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102392.	6.5	163
58	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 578-585.	0.9	161
59	Genetic influence on cytokine production in meningococcal disease. Lancet, The, 1997, 349, 1912-1913.	13.7	159
60	Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: Identification of the interleukinâ€7 signaling pathway in tissues with lymphoid neogenesis. Arthritis and Rheumatism, 2007, 56, 2492-2502.	6.7	156
61	Marked differences in fine specificity and isotype usage of the antiâ€“citrullinated protein antibody in health and disease. Arthritis and Rheumatism, 2008, 58, 3000-3008.	6.7	156
62	Fine Mapping Seronegative and Seropositive Rheumatoid Arthritis to Shared and Distinct HLA Alleles by Adjusting for the Effects of Heterogeneity. American Journal of Human Genetics, 2014, 94, 522-532.	6.2	156
63	The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Annals of the Rheumatic Diseases, 2011, 70, 1039-1046.	0.9	155
64	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. Annals of the Rheumatic Diseases, 2010, 69, 1589-1595.	0.9	152
65	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. PLoS Genetics, 2013, 9, e1003394.	3.5	146
66	Validation of a prediction rule for disease outcome in patients with recentâ€onset undifferentiated arthritis: Moving toward individualized treatment decisionâ€making. Arthritis and Rheumatism, 2008, 58, 2241-2247.	6.7	145
67	Genetics of rheumatoid arthritis: what have we learned?. Immunogenetics, 2011, 63, 459-466.	2.4	142
68	Value of antiâ€“modified citrullinated vimentin and thirdâ€generation antiâ€“cyclic citrullinated peptide compared with secondâ€generation antiâ€“cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2232-2241.	6.7	138
69	Protection against antiâ€“citrullinated protein antibodyâ€“positive rheumatoid arthritis is predominantly associated with HLAâ€“DRB1*1301: A metaâ€analysis of HLAâ€“DRB1 associations with antiâ€“citrullinated protein antibodyâ€“positive and antiâ€“citrullinated protein antibodyâ€“negative rheumatoid arthritis in four European populations. Arthritis and Rheumatism, 2010, 62, 1236-1245.	6.7	135
70	A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 1.	3.5	135
71	Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Research and Therapy, 2008, 10, 205.	3.5	128
72	ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. Annals of the Rheumatic Diseases, 2013, 72, 1646-1653.	0.9	127

#	Article	IF	Citations
73	Determination of tumour necrosis factor-Î± and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. Journal of Immunological Methods, 1998, 218, 63-71.	1.4	126
74	Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 1999-2002.	6.7	126
75	Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1824-1830.	0.9	126
76	The HLAâ€“DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis and Rheumatism, 2007, 56, 425-432.	6.7	124
77	Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 2830-2839.	6.7	123
78	Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes. Nature Genetics, 2018, 50, 1366-1374.	21.4	122
79	Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1282-1284.	0.9	120
80	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Annals of the Rheumatic Diseases, 2011, 70, 188-193.	0.9	118
81	Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2019, 7, 6-11.	3.4	118
82	FUNCTIONAL ANALYSIS OF LINKER-SCAN MUTANTS SPANNING THE â^'376, â^'308, â^'244, AND â^'238 POLYMORPHIC SITES OF THE TNF-Î± PROMOTER. Cytokine, 2001, 14, 316-323.	3.2	116
83	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology, 2012, 51, 2204-2214.	1.9	115
84	Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1897-1904.	0.9	114
85	Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 1757-1764.	0.9	113
86	The jointâ€“gut axis in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2010, 4, 257-268.	1.3	112
87	The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA: Table 1. Rheumatology, 2016, 55, 199-209.	1.9	112
88	Production of IL-1Î² and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 172-179.	2.3	111
89	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, 1761-1768.	0.9	111
90	Cutting Edge: TNFR-Shedding by CD4+CD25+ Regulatory T Cells Inhibits the Induction of Inflammatory Mediators. Journal of Immunology, 2008, 180, 2747-2751.	0.8	108

#	Article	IF	Citations
91	An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthritis and Cartilage, 2013, 21, 918-922.	1.3	108
92	Pain in hand osteoarthritis is associated with inflammation: the value of ultrasound. Annals of the Rheumatic Diseases, 2010, 69, 1367-1369.	0.9	107
93	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. Journal of Rheumatology, 2015, 42, 572-579.	2.0	107
94	Thumb base involvement in symptomatic hand osteoarthritis is associated with more pain and functional disability: Table 1. Annals of the Rheumatic Diseases, 2010, 69, 585-587.	0.9	106
95	Impaired innate immunity predicts frailty in old age. The Leiden 85-plus study. Experimental Gerontology, 2004, 39, 1407-1414.	2.8	105
96	Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility. Lancet, The, 1998, 352, 1282-1283.	13.7	104
97	Identification of citrullinated vimentin peptides as T cell epitopes in HLAâ€“DR4â€“positive patients with rheumatoid arthritis. Arthritis and Rheumatism, 2010, 62, 117-125.	6.7	103
98	An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis and Rheumatism, 2005, 52, 2637-2644.	6.7	102
99	Baseline serum adipokine levels predict radiographic progression in early rheumatoid arthritis. Arthritis and Rheumatism, 2011, 63, 2567-2574.	6.7	102
100	Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 807-812.	0.9	99
101	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmunity Reviews, 2014, 13, 225-230.	5.8	99
102	De Novo Generation and Enhanced Suppression of Human CD4+CD25+ Regulatory T Cells by Retinoic Acid. Journal of Immunology, 2009, 183, 4119-4126.	0.8	98
103	Platelets and autoimmunity. European Journal of Clinical Investigation, 2013, 43, 746-757.	3.4	98
104	Rheumatoid arthritis risk allele PTPRC is also associated with response to antiâ€“tumor necrosis factor Î± therapy. Arthritis and Rheumatism, 2010, 62, 1849-1861.	6.7	95
105	Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment. Annals of Internal Medicine, 2016, 164, 523.	3.9	95
106	Immature Dendritic Cells Suppress Collagen-Induced Arthritis by In Vivo Expansion of CD49b+ Regulatory T Cells. Journal of Immunology, 2006, 177, 3806-3813.	0.8	94
107	Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1375-1381.	0.9	94
108	Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus, 2014, 23, 31-38.	1.6	94

#	Article	IF	Citations
109	Understanding the genetic contribution to rheumatoid arthritis. Current Opinion in Rheumatology, 2005, 17, 299-304.	4.3	92
110	The Devil in the Details: The Emerging Role of Anticitrulline Autoimmunity in Rheumatoid Arthritis. Journal of Immunology, 2005, 175, 5575-5580.	0.8	92
111	Animal models for arthritis: innovative tools for prevention and treatment. Annals of the Rheumatic Diseases, 2011, 70, 1357-1362.	0.9	92
112	Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Annals of the Rheumatic Diseases, 2015, 74, 1225-1232.	0.9	92
113	Association of a singleâ€nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 2242-2247.	6.7	91
114	Preventing progression from arthralgia to arthritis: targeting the right patients. Nature Reviews Rheumatology, 2018, 14, 32-41.	8.0	91
115	Brain histopathology in patients with systemic lupus erythematosus: identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology, 2017, 56, 77-86.	1.9	90
116	Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study. Arthritis Research and Therapy, 2015, 17, 232.	3.5	88
117	Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Therapeutic Advances in Musculoskeletal Disease, 2017, 9, 249-262.	2.7	88
118	The B cell response to citrullinated antigens in the development of rheumatoid arthritis. Nature Reviews Rheumatology, 2018, 14, 157-169.	8.0	88
119	Immunomodulatory Dendritic Cells Inhibit Th1 Responses and Arthritis via Different Mechanisms. Journal of Immunology, 2007, 179, 1506-1515.	0.8	86
120	Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology, 2008, 159, 609-615.	3.7	86
121	Remission induction therapy with methotrexate and prednisone in patients with early rheumatoid and undifferentiated arthritis (the IMPROVED study). Annals of the Rheumatic Diseases, 2012, 71, 1472-1477.	0.9	86
122	Comparative Efficacy of Novel DMARDs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with Inadequate Response to Conventional DMARDs: A Network Meta-Analysis. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 409-423.	0.9	86
123	Allele-specific quantification of tumor necrosis factor Î± (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes and Immunity, 2001, 2, 135-144.	4.1	85
124	Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis and Rheumatism, 2009, 60, 1255-1260.	6.7	84
125	Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?. Annals of the Rheumatic Diseases, 2016, 75, 1308-1314.	0.9	84
126	Optimizing human fertility and survival. Nature Medicine, 2001, 7, 873-873.	30.7	83

#	Article	IF	Citations
127	Prevention of autoimmune rheumatic disease: state of the art and future perspectives. Annals of the Rheumatic Diseases, 2010, 69, 2062-2066.	0.9	83
128	Structural Analysis of Variable Domain Glycosylation of Anti-Citrullinated Protein Antibodies in Rheumatoid Arthritis Reveals the Presence of Highly Sialylated Glycans. Molecular and Cellular Proteomics, 2017, 16, 278-287.	3.8	82
129	Triple Positivity for Antiâ€“Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Antiâ€“Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1721-1731.	5.6	81
130	Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Research and Therapy, 2006, 8, R165.	3.5	80
131	Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: Relationship to functional capacity and ventricular arrhythmias. Arthritis and Rheumatism, 2011, 63, 3969-3978.	6.7	80
132	Nâ€Linked Glycans in the Variable Domain of IgG Antiâ€“Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 1626-1633.	5.6	80
133	Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Research and Therapy, 2011, 13, R150.	3.5	79
134	Associations, populations, and the truth: Recommendations for genetic association studies inArthritis & Rheumatism. Arthritis and Rheumatism, 2004, 50, 2066-2071.	6.7	78
135	Redefining the HLA and RA association: To be or not to be anti-CCP positive. Journal of Autoimmunity, 2005, 25, 21-25.	6.5	75
136	A Large-Scale Rheumatoid Arthritis Genetic Study Identifies Association at Chromosome 9q33.2. PLoS Genetics, 2008, 4, e1000107.	3.5	75
137	Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Annals of the Rheumatic Diseases, 2020, 79, 472-480.	0.9	74
138	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the â€˜AMC-Senshuâ€™ method. Annals of the Rheumatic Diseases, 2013, 72, 148-150.	0.9	73
139	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nature Communications, 2016, 7, 12460.	12.8	73
140	Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1170-1176.	0.9	72
141	Adipocyteâ€derived lipids modulate CD4⁺ Tâ€cell function. European Journal of Immunology, 2013, 43, 1578-1587.	2.9	71
142	The association of treatment response and joint damage with ACPA-status in recent-onset RA: a subanalysis of the 8-year follow-up of the BeSt study. Annals of the Rheumatic Diseases, 2012, 71, 245-248.	0.9	70
143	Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 769-775.	0.9	70
144	Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17180-17185.	7.1	69

#	Article	IF	Citations
145	Interleukin-10 promoter single-nucleotide polymorphisms as markers for disease susceptibility and disease severity in leprosy. Genes and Immunity, 2004, 5, 592-595.	4.1	69
146	Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Annals of the Rheumatic Diseases, 2009, 68, 1011-1016.	0.9	69
147	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1259-1263.	0.9	69
148	Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Quality of Life Research, 2003, 12, 635-644.	3.1	68
149	The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1110-1116.	0.9	68
150	In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis. Annals of the Rheumatic Diseases, 2013, 72, 930-934.	0.9	68
151	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Arthritis Research and Therapy, 2015, 17, 339.	3.5	67
152	Treatment with TNF-Î± inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. Osteoarthritis and Cartilage, 2010, 18, 1256-1262.	1.3	65
153	Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nature Genetics, 2010, 42, 814-816.	21.4	65
154	Immunogenetics of rheumatoid arthritis: Understanding functional implications. Journal of Autoimmunity, 2015, 64, 74-81.	6.5	65
155	Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics, 2010, 11, 163-175.	1.3	64
156	Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Annals of the Rheumatic Diseases, 2012, 71, 707-709.	0.9	64
157	Feasibility of Adenovirus-Mediated Nonsurgical Synovectomy in Collagen-Induced Arthritis-Affected Rhesus Monkeys. Human Gene Therapy, 1999, 10, 1139-1149.	2.7	63
158	Criteria for early rheumatoid arthritis: From Bayes' law revisited to new thoughts on pathogenesis. Arthritis and Rheumatism, 2002, 46, 1155-1159.	6.7	63
159	CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Human Genetics, 2005, 118, 58-66.	3.8	63
160	Osteophytes and joint space narrowing are independently associated with pain in finger joints in hand osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 1835-1837.	0.9	63
161	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 209.	3.5	63
162	Low innate production of interleukin-1Î² and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthritis and Cartilage, 2010, 18, 942-947.	1.3	62

#	Article	IF	Citations
163	Prospective Study of Clinical Phenotypes in Neuropsychiatric Systemic Lupus Erythematosus; Multidisciplinary Approach to Diagnosis and Therapy. Journal of Rheumatology, 2012, 39, 2118-2126.	2.0	62
164	Neuropsychiatric manifestations in patients with systemic lupus erythematosus: epidemiology and radiology pointing to an immune-mediated cause. Annals of the Rheumatic Diseases, 2013, 72, ii76-ii79.	0.9	62
165	A method to decipher pleiotropy by detecting underlying heterogeneity driven by hidden subgroups applied to autoimmune and neuropsychiatric diseases. Nature Genetics, 2016, 48, 803-810.	21.4	62
166	Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus, 2007, 16, 329-334.	1.6	61
167	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Annals of the Rheumatic Diseases, 2012, 71, 268-274.	0.9	61
168	Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology, 2014, 53, 2122-2124.	1.9	60
169	Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19966-19970.	7.1	59
170	Activation of human basophils by combined tollâ€like receptorâ€•and <scp>F</scp>cÎµ<scp>RI</scp>â€triggering can promote <scp>T</scp>h2 skewing of naive <scp>T</scp> helper cells. European Journal of Immunology, 2014, 44, 386-396.	2.9	59
171	An extended HLA-DQ-DR haplotype rather than DRB1 alone contributes to RA predisposition. Immunogenetics, 1998, 48, 394-401.	2.4	58
172	Evaluation of Magnetic Resonance Imagingâ€“Detected Tenosynovitis in the Hand and Wrist in Early Arthritis. Arthritis and Rheumatology, 2015, 67, 869-876.	5.6	58
173	Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes and Immunity, 1999, 1, 91-96.	4.1	57
174	Exploratory analysis of four polymorphisms in humanGGHandFPGSgenes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics, 2007, 8, 141-150.	1.3	57
175	Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discovery Today, 2007, 12, 125-131.	6.4	57
176	Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study. RMD Open, 2015, 1, e000041-e000041.	3.8	57
177	Evidence for non-random distribution of FcÎ³ receptor genotype combinations. Immunogenetics, 2003, 55, 240-246.	2.4	56
178	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Research and Therapy, 2016, 18, 198.	3.5	56
179	MR signal intensity: staying on the bright side in MR image interpretation. RMD Open, 2018, 4, e000728.	3.8	56
180	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis and Rheumatism, 2011, 63, 1823-1832.	6.7	55

#	Article	IF	Citations
181	PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 512-515.	0.9	55
182	Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. Brain, 2016, 139, 1447-1457.	7.6	54
183	Selective Involvement of the Amygdala in Systemic Lupus Erythematosus. PLoS Medicine, 2006, 3, e499.	8.4	53
184	Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Annals of the Rheumatic Diseases, 2010, 69, 1342-1345.	0.9	53
185	New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. International Journal of Epidemiology, 2015, 44, 1706-1721.	1.9	53
186	Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1751-1754.	0.9	53
187	Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis. Science Translational Medicine, 2020, 12, .	12.4	53
188	Onset of rheumatoid arthritis after COVID-19: coincidence or connected?. Annals of the Rheumatic Diseases, 2021, 80, 1096-1098.	0.9	53
189	Targeted lipidomics reveals activation of resolution pathways in knee osteoarthritis in humans. Osteoarthritis and Cartilage, 2017, 25, 1150-1160.	1.3	52
190	Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands. PLoS Medicine, 2020, 17, e1003296.	8.4	52
191	Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNFâˆ'308A in systemic lupus erythematosus. Genes and Immunity, 2001, 2, 373-380.	4.1	51
192	Association of the risk of osteoarthritis with high innate production of interleukin-1Î² and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis and Rheumatism, 2005, 52, 1443-1450.	6.7	51
193	Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+T cells upon immune-complex uptake in vivo. Immunology, 2006, 119, 499-506.	4.4	51
194	Degree of synovitis on MRI by comprehensive whole knee semi-quantitative scoring method correlates with histologic and macroscopic features of synovial tissue inflammation in knee osteoarthritis. Osteoarthritis and Cartilage, 2014, 22, 1606-1613.	1.3	51
195	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	2.7	51
196	B-cell receptor sequencing of anti-citrullinated protein antibody (ACPA) IgG-expressing B cells indicates a selective advantage for the introduction of N -glycosylation sites during somatic hypermutation. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2017-212052.	0.9	51
197	Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study. Annals of the Rheumatic Diseases, 2018, 77, 111-118.	0.9	51
198	Interleukinâ€"10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. Immunogenetics, 2003, 54, 896-899.	2.4	50

#	Article	IF	Citations
199	Gene Transfer of Tissue Inhibitor of Metalloproteinases-3 Reverses the Inhibitory Effects of TNF-Î± on Fas-Induced Apoptosis in Rheumatoid Arthritis Synovial Fibroblasts. Journal of Immunology, 2005, 174, 6524-6531.	0.8	50
200	Tractâ€based spatial statistics on diffusion tensor imaging in systemic lupus erythematosus reveals localized involvement of white matter tracts. Arthritis and Rheumatism, 2010, 62, 3716-3721.	6.7	50
201	Ability of Interleukinâ€33â€“ and Immune Complexâ€“Triggered Activation of Human Mast Cells to Downâ€Regulate Monocyteâ€Mediated Immune Responses. Arthritis and Rheumatology, 2015, 67, 2343-2353.	5.6	50
202	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Annals of the Rheumatic Diseases, 2010, 69, 696-699.	0.9	49
203	Communication between human mast cells and <scp>CD</scp>4⁺<scp>T</scp> cells through antigenâ€dependent interactions. European Journal of Immunology, 2013, 43, 1758-1768.	2.9	49
204	A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. NeuroImage: Clinical, 2015, 8, 337-344.	2.7	49
205	Seronegative and seropositive RA: alike but different?. Nature Reviews Rheumatology, 2015, 11, 8-9.	8.0	49
206	Imaging modalities in central nervous system systemic lupus erythematosus. Current Opinion in Rheumatology, 2001, 13, 383-388.	4.3	48
207	Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Human Immunology, 2002, 63, 281-285.	2.4	48
208	MRI of hand and foot joints of patients with anticitrullinated peptide antibody positive arthralgia without clinical arthritis. Annals of the Rheumatic Diseases, 2013, 72, 1540-1544.	0.9	48
209	IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities. Rheumatology, 2015, 54, 728-735.	1.9	48
210	Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Annals of Neurology, 2000, 48, 641-646.	5.3	47
211	Rituximab in early systemic sclerosis. RMD Open, 2017, 3, e000384.	3.8	47
212	Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden early arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1366-1369.	0.9	46
213	Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis. Seminars in Arthritis and Rheumatism, 2019, 48, 967-975.	3.4	46
214	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, 1461-1464.	0.9	45
215	Demyelinating disease in SLE: Is it multiple sclerosis or lupus?. Best Practice and Research in Clinical Rheumatology, 2013, 27, 405-424.	3.3	45
216	Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study). Annals of the Rheumatic Diseases, 2014, 73, 396-400.	0.9	45

#	Article	IF	Citations
217	The Course of Bone Marrow Edema in Early Undifferentiated Arthritis and Rheumatoid Arthritis: A Longitudinal Magnetic Resonance Imaging Study at Bone Level. Arthritis and Rheumatology, 2016, 68, 1080-1088.	5.6	45
218	Emerging patterns of risk factor make-up enable subclassification of rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 1728-1735.	6.7	44
219	Autoimmunity in rheumatoid arthritis: different antigensâ€"common principles. Annals of the Rheumatic Diseases, 2013, 72, ii132-ii136.	0.9	44
220	Do Comorbidities Play a Role in Hand Osteoarthritis Disease Burden? Data from the Hand Osteoarthritis in Secondary Care Cohort. Journal of Rheumatology, 2017, 44, 1659-1666.	2.0	44
221	Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus. American Journal of Neuroradiology, 2003, 24, 850-4.	2.4	44
222	Genetic variants in the prediction of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1694-1696.	0.9	43
223	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. Arthritis Research and Therapy, 2016, 18, 285.	3.5	43
224	Aiming for a simpler early arthritis MRI protocol: can Gd contrast administration be eliminated?. European Radiology, 2015, 25, 1520-1527.	4.5	42
225	Apoptosis of cultured rat glomerular mesangial cells induced by IgG2a monoclonal anti-Thy-1 antibodies. Kidney International, 1996, 49, 403-412.	5.2	41
226	Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis and Rheumatism, 2001, 44, 570-577.	6.7	41
227	Body mass index and alignment and their interaction as risk factors for progression of knees with radiographic signs of osteoarthritis. Osteoarthritis and Cartilage, 2011, 19, 1117-1122.	1.3	41
228	Metabolic Profiling Reveals Differences in Concentrations of Oxylipins and Fatty Acids Secreted by the Infrapatellar Fat Pad of Donors With Endâ€Stage Osteoarthritis and Normal Donors. Arthritis and Rheumatism, 2013, 65, 2606-2614.	6.7	41
229	Adipocytes Modulate the Phenotype of Human Macrophages through Secreted Lipids. Journal of Immunology, 2013, 191, 1356-1363.	0.8	41
230	Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example. Arthritis and Rheumatology, 2017, 69, 926-931.	5.6	41
231	Polymorphism within the tumor necrosis factor Î± (TNF) promoter region in patients with ankylosing spondylitis. Human Immunology, 1999, 60, 140-144.	2.4	40
232	IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine, 2005, 29, 215-228.	3.2	40
233	Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity. Arthritis Research and Therapy, 2006, 8, 216.	3.5	40
234	Determinants of absence of osteoarthritis in old age. Scandinavian Journal of Rheumatology, 2011, 40, 68-73.	1.1	40

#	Article	IF	Citations
235	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 270-276.	0.9	40
236	Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 2038-2046.	0.9	40
237	Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis. RMD Open, 2016, 2, e000159.	3.8	40
238	The BeSt story: on strategy trials in rheumatoid arthritis. Current Opinion in Rheumatology, 2009, 21, 291-298.	4.3	39
239	Baseline autoantibody profile in rheumatoid arthritisÂis associated with early treatment response but not long-term outcomes. Arthritis Research and Therapy, 2018, 20, 33.	3.5	39
240	Sustained drug-free remission in rheumatoid arthritis after DAS-driven or non-DAS-driven therapy: a comparison of two cohort studies. Rheumatology, 2012, 51, 1120-1128.	1.9	38
241	A Multibiomarker Disease Activity Score for Rheumatoid Arthritis Predicts Radiographic Joint Damage in the BeSt Study. Journal of Rheumatology, 2014, 41, 2114-2119.	2.0	38
242	When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). RMD Open, 2016, 2, e000221.	3.8	38
243	Using a reference when defining an abnormal MRI reduces false-positive MRI resultsâ€"a longitudinal study in two cohorts at risk for rheumatoid arthritis. Rheumatology, 2017, 56, 1700-1706.	1.9	38
244	Functional Killer Ig-Like Receptors on Human Memory CD4+ T Cells Specific for Cytomegalovirus. Journal of Immunology, 2009, 182, 4175-4182.	0.8	37
245	Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Arthritis Research and Therapy, 2016, 18, 23.	3.5	37
246	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. PLoS ONE, 2014, 9, e102163.	2.5	37
247	Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 1915-1923.	0.9	36
248	Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Human Genetics, 1995, 96, 493.	3.8	35
249	Systemic Lupus Erythematosus: Diagnostic Application of Magnetization Transfer Ratio Histograms in Patients with Neuropsychiatric Symptomsâ€"Initial Results. Radiology, 2002, 222, 722-728.	7.3	35
250	Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. Annals of the Rheumatic Diseases, 2010, 69, 727-729.	0.9	35
251	Epistasis between two HLA antigens defines a subset of individuals at a very high risk for ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 72, 974-978.	0.9	35
252	On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1616-1620.	0.9	35

#	Article	IF	Citations
253	Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatology and Therapy, 2021, 8, 41-61.	2.3	35
254	The influence of synovial fluid on adenovirus-mediated gene transfer to the synovial tissue. Arthritis and Rheumatism, 2001, 44, 48-52.	6.7	34
255	Detection of change in CNS involvement in neuropsychiatric SLE: A magnetization transfer study. Journal of Magnetic Resonance Imaging, 2006, 24, 812-816.	3.4	34
256	Integration of Sequence Data from a Consanguineous Family with Genetic Data from an Outbred Population Identifies PLB1 as a Candidate Rheumatoid Arthritis Risk Gene. PLoS ONE, 2014, 9, e87645.	2.5	34
257	Aiming for a shorter rheumatoid arthritis MRI protocol: can contrast-enhanced MRI replace T2 for the detection of bone marrow oedema?. European Radiology, 2014, 24, 2614-2622.	4.5	34
258	The production and secretion of complement component C1q by human mast cells. Molecular Immunology, 2016, 78, 164-170.	2.2	34
259	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. Annals of the Rheumatic Diseases, 2019, 78, 908-916.	0.9	34
260	Tumor Necrosis Factor-Î± Genetic Predisposing Factors Can Influence Clinical Severity in Nephropathia Epidemica. Viral Immunology, 2006, 19, 558-564.	1.3	33
261	Clinical pharmacogenetic model to predict response of MTX monotherapy in patients with established rheumatoid arthritis after DMARD failure. Pharmacogenomics, 2012, 13, 1087-1094.	1.3	33
262	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. Journal of Autoimmunity, 2015, 62, 39-44.	6.5	33
263	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Research and Therapy, 2019, 21, 28.	3.5	33
264	Anti-Inflammatory and Proresolving Effects of the Omega-6 Polyunsaturated Fatty Acid Adrenic Acid. Journal of Immunology, 2020, 205, 2840-2849.	0.8	33
265	Biomarkers for Radiographic Progression in Rheumatoid Arthritis. Current Pharmaceutical Design, 2014, 21, 147-169.	1.9	33
266	Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo. Molecular Immunology, 2006, 43, 2045-2050.	2.2	32
267	Improved early identification of arthritis: evaluating the efficacy of Early ArthritisRecognitionClinics. Annals of the Rheumatic Diseases, 2013, 72, 1295-1301.	0.9	32
268	IgE and ILâ€ß3â^'mediated triggering of human basophils inhibits TLR4â^'induced monocyte activation. European Journal of Immunology, 2014, 44, 3045-3055.	2.9	32
269	Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology, 2016, 55, 357-366.	1.9	32
270	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1084-1089.	0.9	32

#	Article	IF	Citations
271	Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. Arthritis Research and Therapy, 2016, 18, 138.	3.5	31
272	Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology, 2018, 57, 1423-1431.	1.9	31
273	Using genetics to prioritize diagnoses for rheumatology outpatients with inflammatory arthritis. Science Translational Medicine, 2020, 12, .	12.4	31
274	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
275	Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 567-570.	0.9	30
276	Personalized medicine: predicting responses to therapy in patients with RA. Current Opinion in Pharmacology, 2013, 13, 463-469.	3.5	30
277	Surface Ig variable domain glycosylation affects autoantigen binding and acts as threshold for human autoreactive B cell activation. Science Advances, 2022, 8, eabm1759.	10.3	30
278	Reactivity of cloned, expressed human FcÎ³RIII isoforms with monoclonal antibodies which distinguish cell-type-specific and allelic forms of FcÎ³RIII. International Immunology, 1990, 2, 303-310.	4.0	29
279	Variation in radiologic joint destruction in rheumatoid arthritis differs between monozygotic and dizygotic twins and pairs of unrelated patients. Arthritis and Rheumatism, 2006, 54, 2028-2030.	6.7	29
280	A Novel Role of Complement Factor C1q in Augmenting the Presentation of Antigen Captured in Immune Complexes to CD8+T Lymphocytes. Journal of Immunology, 2007, 178, 7581-7586.	0.8	29
281	Evaluation of the diagnostic accuracy of hand and foot MRI for early Rheumatoid Arthritis. Rheumatology, 2017, 56, 1367-1377.	1.9	29
282	Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the AGREE study. RMD Open, 2018, 4, e000564.	3.8	29
283	Identification of regulators of the myofibroblast phenotype of primary dermal fibroblasts from early diffuse systemic sclerosis patients. Scientific Reports, 2019, 9, 4521.	3.3	29
284	Machine Learning Electronic Health Record Identification of Patients with Rheumatoid Arthritis: Algorithm Pipeline Development and Validation Study. JMIR Medical Informatics, 2020, 8, e23930.	2.6	29
285	Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus, 2013, 22, 171-179.	1.6	28
286	Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. Journal of Autoimmunity, 2010, 34, 390-399.	6.5	27
287	Comparison of methodologies for analysing the progression of joint destruction in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2013, 42, 182-189.	1.1	27
288	Follow-up study of inflammatory ultrasound features in hand osteoarthritis over a period of 3 months: variable as well as constant. Osteoarthritis and Cartilage, 2014, 22, 40-43.	1.3	27

#	Article	IF	Citations
289	Mortality in osteoarthritis patients. Scandinavian Journal of Rheumatology, 2015, 44, 70-73.	1.1	27
290	Breach of autoreactive B cell tolerance by post-translationally modified proteins. Annals of the Rheumatic Diseases, 2017, 76, 1449-1457.	0.9	27
291	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.8	26
292	Association study of candidate genes for the progression of hand osteoarthritis. Osteoarthritis and Cartilage, 2013, 21, 565-569.	1.3	26
293	HLA and rheumatoid arthritis: How do they connect?. Annals of Medicine, 2014, 46, 304-310.	3.8	26
294	Gene Therapy and Cement Injection for Restabilization of Loosened Hip Prostheses. Human Gene Therapy, 2008, 19, 83-96.	2.7	25
295	The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Seminars in Immunopathology, 2014, 36, 313-325.	6.1	25
296	Clustering of hand osteoarthritis progression and its relationship to progression of osteoarthritis at the knee. Annals of the Rheumatic Diseases, 2014, 73, 567-572.	0.9	25
297	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. Rheumatology, 2015, 54, 1930-1932.	1.9	25
298	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. Rheumatology, 2018, 57, 1707-1720.	1.9	25
299	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39. Annals of the Rheumatic Diseases, 2019, 78, 1055-1061.	0.9	25
300	Depression and anxiety associate with less remission after 1 year in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, e1-e1.	0.9	25
301	Drug-free remission: is it already possible?. Current Opinion in Rheumatology, 2011, 23, 266-272.	4.3	24
302	Crowdsourcing genetic prediction of clinical utility in the Rheumatoid Arthritis Responder Challenge. Nature Genetics, 2013, 45, 468-469.	21.4	24
303	TAC-TIC use of tacrolimus-based regimens in lupus nephritis. Lupus Science and Medicine, 2016, 3, e000169.	2.7	24
304	Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open, 2016, 2, e000262.	3.8	24
305	Evaluating joint destruction in rheumatoid arthritis: is it necessary to radiograph both hands and feet?. Annals of the Rheumatic Diseases, 2013, 72, 345-349.	0.9	23
306	Are Rheumatoid Arthritis Patients Discernible from Other Early Arthritis Patients Using 1.5T Extremity Magnetic Resonance Imaging? A Large Cross-sectional Study. Journal of Rheumatology, 2014, 41, 1630-1637.	2.0	23

#	Article	IF	Citations
307	Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study. Journal of Rheumatology, 2015, 42, 1383-1391.	2.0	23
308	Quality indicators in rheumatoid arthritis: results from the METEOR database. Rheumatology, 2015, 54, 1630-1639.	1.9	23
309	Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies. Annals of the Rheumatic Diseases, 2016, 75, 2201-2207.	0.9	23
310	The increased ability to present citrullinated peptides is not unique to HLA-SE molecules: arginine-to-citrulline conversion also enhances peptide affinity for HLA-DQ molecules. Arthritis Research and Therapy, 2016, 18, 254.	3.5	23
311	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. Arthritis Research and Therapy, 2017, 19, 115.	3.5	23
312	Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open, 2020, 6, e001370.	3.8	23
313	IgG Antiâ€“Citrullinated Protein Antibody Variable Domain Glycosylation Increases Before the Onset of Rheumatoid Arthritis and Stabilizes Thereafter: A Crossâ€Sectional Study Encompassing ~1,500 Samples. Arthritis and Rheumatology, 2022, 74, 1147-1158.	5.6	23
314	Diabetes insipidus in metastatic cancer: Two case reports with review of the literature. Annals of Oncology, 2000, 11, 891-895.	1.2	22
315	Validity and responsiveness of the Michigan Hand Questionnaire in patients with systemic sclerosis. Rheumatology, 2016, 55, 1386-1393.	1.9	22
316	Health-related quality of life in patients with systemic sclerosis: evolution over time and main determinants. Rheumatology, 2021, 60, 3646-3655.	1.9	22
317	Association between Several Clinical and Radiological Determinants with Long-Term Clinical Progression and Good Prognosis of Lower Limb Osteoarthritis. PLoS ONE, 2011, 6, e25426.	2.5	22
318	Doyle Index is a valuable additional pain measure in osteoarthritis. Osteoarthritis and Cartilage, 2010, 18, 1046-1050.	1.3	21
319	Can we achieve true drug-free remission in patients with RA?. Nature Reviews Rheumatology, 2010, 6, 68-70.	8.0	21
320	Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2012, 41, 359-365.	1.1	21
321	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. Annals of the Rheumatic Diseases, 2013, 72, 1059-1063.	0.9	21
322	Studies on ageing and the severity of radiographic joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 222.	3.5	21
323	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Research and Therapy, 2015, 17, 276.	3.5	21
324	Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. Journal of Rheumatology, 2006, 33, 1747-53.	2.0	21

#	Article	IF	Citations
325	Allele dose association of theC5orf30rs26232 variant with joint damage in rheumatoid arthritis. Arthritis and Rheumatism, 2013, 65, n/a-n/a.	6.7	20
326	Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus. Rheumatology, 2017, 56, 1407-1416.	1.9	20
327	Functional limitations in the phase of clinically suspect arthralgia are as serious as in early clinical arthritis; a longitudinal study. RMD Open, 2017, 3, e000419.	3.8	20
328	Is the Site of Back Pain Related to the Location of Magnetic Resonance Imaging Lesions in Patients With Chronic Back Pain? Results From the Spondyloarthritis Caught Early Cohort. Arthritis Care and Research, 2017, 69, 717-723.	3.4	20
329	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Research and Therapy, 2017, 19, 190.	3.5	20
330	ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. Arthritis Research and Therapy, 2019, 21, 121.	3.5	20
331	Changes in Plasma FcRIII Demonstrate Increasing Receptor Production during Late Pregnancy and after Preterm Birth. Pediatric Research, 1992, 32, 505-508.	2.3	19
332	Recommendations for publication of genetic association studies inArthritis & Rheumatism. Arthritis and Rheumatism, 2011, 63, 2839-2847.	6.7	19
333	A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, R108.	3.5	19
334	IL2RA is associated with persistence of rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 244.	3.5	19
335	Body mass index and extent of MRI-detected inflammation: opposite effects in rheumatoid arthritis versus other arthritides and asymptomatic persons. Arthritis Research and Therapy, 2016, 18, 245.	3.5	19
336	Repeated FcÎµRI triggering reveals modified mast cell function related to chronic allergic responses in tissue. Journal of Allergy and Clinical Immunology, 2016, 138, 869-880.	2.9	19
337	Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12â€‰months of tapering anti-rheumatic drugs. Arthritis Research and Therapy, 2019, 21, 268.	3.5	19
338	Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. Lupus, 2020, 29, 1892-1901.	1.6	19
339	Lupus and the central nervous system. Lupus, 2008, 17, 376-379.	1.6	18
340	Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 883-889.	0.9	18
341	Abatacept decreases disease activity in the absence of CD4+ T cells in a collagen-induced arthritis model. Arthritis Research and Therapy, 2015, 17, 220.	3.5	18
342	The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis. Current Opinion in Rheumatology, 2016, 28, 275-281.	4.3	18

#	Article	IF	Citations
343	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, 174.	3.5	18
344	Association of Antiâ€“Topoisomerase I Antibodies of the IgM Isotype With Disease Progression in Antiâ€“Topoisomerase Iâ€“Positive Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1897-1904.	5.6	18
345	The role of interleukin 10 promoter polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. Journal of Rheumatology, 2005, 32, 1571-5.	2.0	18
346	High innate production of interleukin-10 and tumor necrosis factor-Î± contributes to susceptibility for non-paraneoplastic Lambertâ€“Eaton myasthenic syndrome. Journal of Neuroimmunology, 2003, 140, 194-197.	2.3	17
347	Hyperpigmentation of the skin due to hydroxychloroquine. Scandinavian Journal of Rheumatology, 2008, 37, 158-158.	1.1	17
348	Validity of joint space width measurements in hand osteoarthritis. Osteoarthritis and Cartilage, 2011, 19, 1349-1355.	1.3	17
349	Serum Pyridinoline Levels and Prediction of Severity of Joint Destruction in Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 1303-1306.	2.0	17
350	Reasons for medical help-seeking behaviour of patients with recent-onset arthralgia. Annals of the Rheumatic Diseases, 2013, 72, 1302-1307.	0.9	17
351	Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis. Annals of the Rheumatic Diseases, 2016, 75, 1501-1505.	0.9	17
352	Progression of Left Ventricular Myocardial Dysfunction in Systemic Sclerosis: A Speckle-tracking Strain Echocardiography Study. Journal of Rheumatology, 2019, 46, 405-415.	2.0	17
353	Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 921-930.	5.6	17
354	Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. Lupus, 2021, 30, 1124-1132.	1.6	17
355	Early aggressive therapy in rheumatoid arthritis: a 'window of opportunity'?. Nature Clinical Practice Rheumatology, 2005, 1, 2-3.	3.2	16
356	Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis. Journal of Rheumatology, 2013, 40, 624-629.	2.0	16
357	Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Research and Therapy, 2015, 17, 325.	3.5	16
358	Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?. Journal of Internal Medicine, 2015, 277, 178-187.	6.0	16
359	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. Annals of the Rheumatic Diseases, 2015, 74, 949-950.	0.9	16
360	Older age is associated with more MRI-detected inflammation in hand and foot joints. Rheumatology, 2016, 55, 2212-2219.	1.9	16

#	Article	IF	Citations
361	Allele-Specific Expression of the IL-1Î± Gene in Human CD4+ T Cell Clones. Journal of Immunology, 2003, 171, 2349-2353.	0.8	15
362	HLA and RA Revisited: Citrullinated Food for the SE Hypothesis, the DR6 Effect, and NIMA. Human Immunology, 2006, 67, 454-459.	2.4	15
363	Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus the rheumatologist's opinion. Clinical Rheumatology, 2014, 33, 461-466.	2.2	15
364	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. Immunobiology, 2015, 220, 422-427.	1.9	15
365	Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents. RMD Open, 2017, 3, e000568.	3.8	15
366	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. Modern Rheumatology, 2012, 22, 15-20.	1.8	15
367	Genetics in rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2003, 17, 703-716.	3.3	14
368	Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3 CR1 and rheumatoid arthritis. Tissue Antigens, 2003, 62, 170-174.	1.0	14
369	An innovative care model coordinated by a physical therapist and nurse practitioner for osteoarthritis of the hip and knee in specialist care: a prospective study. Rheumatology International, 2013, 33, 1821-1828.	3.0	14
370	Differential methylation within the major histocompatibility complex region in rheumatoid arthritis: a replication study. Rheumatology, 2014, 53, 2317-2318.	1.9	14
371	Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH. Arthritis Research and Therapy, 2015, 17, 108.	3.5	14
372	2014 treat-to-target RA recommendationsâ€"strategy is key. Nature Reviews Rheumatology, 2015, 11, 509-511.	8.0	14
373	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Annals of the Rheumatic Diseases, 2018, 77, 1087-1088.	0.9	14
374	Performance of the proposed ACRâ€"EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms. RMD Open, 2019, 5, e000895.	3.8	14
375	Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA. Annals of the Rheumatic Diseases, 2020, 79, e124-e124.	0.9	14
376	Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis. Arthritis and Rheumatology, 2021, 73, 2338-2347.	5.6	14
377	Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course. Annals of the Rheumatic Diseases, 2022, 81, 169-174.	0.9	14
378	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 937-943.	0.9	14

#	Article	IF	Citations
379	Rheumatoid arthritis: the goal rather than the health-care provider is key. Lancet, The, 2006, 367, 450-452.	13.7	13
380	Genetic markers of treatment response in rheumatoid arthritis. Current Rheumatology Reports, 2006, 8, 369-377.	4.7	13
381	Treatment strategies in recent onset rheumatoid arthritis. Current Opinion in Rheumatology, 2011, 23, 241-244.	4.3	13
382	Variants of gene for microsomal prostaglandin E2 synthase show association with disease and severe inflammation in rheumatoid arthritis. European Journal of Human Genetics, 2011, 19, 908-914.	2.8	13
383	The development of a simple questionnaire to screen patients with SLE for the presence of neuropsychiatric symptoms in routine clinical practice. Lupus, 2011, 20, 485-492.	1.6	13
384	Predictive factors of radiological progression after 2â€…years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. RMD Open, 2016, 2, e000172.	3.8	13
385	Genomic Influences on Susceptibility and Severity of Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2017, 43, 347-361.	1.9	13
386	Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Seminars in Arthritis and Rheumatism, 2020, 50, 140-148.	3.4	13
387	Evolution of interstitial lung disease one year after hematopoietic stem cell transplantation or cyclophosphamide for systemic sclerosis. Arthritis Care and Research, 2020, , .	3.4	13
388	Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population. Annals of the Rheumatic Diseases, 2022, 81, e69-e69.	0.9	13
389	Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI. European Radiology, 2021, 31, 8208-8217.	4.5	13
390	Control of systemic B cell-mediated autoimmune disease by nonmyeloablative conditioning and major histocompatibility complex-mismatched allogeneic bone marrow transplantation. Blood, 2005, 105, 2991-2994.	1.4	12
391	Genomeâ€wide singleâ€nucleotide polymorphism studies in rheumatology: Hype or hope?. Arthritis and Rheumatism, 2008, 58, 2591-2597.	6.7	12
392	Are Baseline High Molecular Weight Adiponectin Levels Associated with Radiographic Progression in Rheumatoid Arthritis and Osteoarthritis?. Journal of Rheumatology, 2014, 41, 853-857.	2.0	12
393	Macrophage migration inhibitory factor (MIF) -173 polymorphism is associated with clinical erythema nodosum in LÃ¶fgrenâ€™s syndrome. Cytokine, 2014, 69, 272-276.	3.2	12
394	Health-care utilization in Dutch systemic sclerosis patients. Clinical Rheumatology, 2014, 33, 825-832.	2.2	12
395	Effectiveness of four dynamic treatment strategies in patients with anticitrullinated protein antibody-negative rheumatoid arthritis: a randomised trial. RMD Open, 2016, 2, e000143.	3.8	12
396	Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA. Annals of the Rheumatic Diseases, 2016, 75, 1891-1898.	0.9	12

#	Article	IF	Citations
397	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Annals of the Rheumatic Diseases, 2018, 77, 1836-1838.	0.9	12
398	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. Arthritis Research and Therapy, 2021, 23, 230.	3.5	12
399	Cerebral magnetic resonance imaging in quiescent Crohnâ€™s disease patients with fatigue. World Journal of Gastroenterology, 2017, 23, 1018.	3.3	12
400	Acitretin-related ossification. Journal of Rheumatology, 2007, 34, 837-8.	2.0	12
401	Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2010, 69, 1239-1242.	0.9	11
402	Disease Activity Monitoring in Rheumatoid Arthritis in Daily Practice: Experiences with METEOR, a Free Online Tool. Journal of Rheumatology, 2010, 37, 2632-2633.	2.0	11
403	Evaluation of the Disease Activity Score in Twentyâ€Eight Jointsâ€“Based Flare Definitions in Rheumatoid Arthritis: Data From a Threeâ€Year Clinical Trial. Arthritis Care and Research, 2015, 67, 1762-1766.	3.4	11
404	Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment. Rheumatology, 2015, 54, 1380-1384.	1.9	11
405	Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors. Annals of the Rheumatic Diseases, 2015, 74, 876-882.	0.9	11
406	Long-term mortality in patients with ST-segment elevation myocardial infarction is associated with anti-citrullinated protein antibodies. International Journal of Cardiology, 2017, 240, 20-24.	1.7	11
407	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. Rheumatology, 2018, 57, 1583-1591.	1.9	11
408	Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis. Rheumatology, 2019, 58, 149-153.	1.9	11
409	Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA. Annals of the Rheumatic Diseases, 2022, 81, 141-143.	0.9	11
410	The effect of corticosteroid medication on quantitative MR parameters of the brain. American Journal of Neuroradiology, 2005, 26, 2475-80.	2.4	11
411	Engraftment of cutaneous fibroblasts within synovial membrane in a nonhuman primate: Short-term results. Joint Bone Spine, 2007, 74, 48-51.	1.6	10
412	The use of data from early arthritis clinics for clinical research. Best Practice and Research in Clinical Rheumatology, 2009, 23, 117-123.	3.3	10
413	Evaluation of the contribution of cumulative levels of inflammation to the variance in joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 72, 307-308.	0.9	10
414	Continued Participation in a Tenâ€Year Tight Control Treatâ€toâ€Target Study in Rheumatoid Arthritis: Why Keep Patients Doing their Best?. Arthritis Care and Research, 2015, 67, 739-745.	3.4	10

#	Article	IF	Citations
415	Rheumatologistsâ€™ adherence to a disease activity score steered treatment protocol in early arthritis patients is less if the target is remission. Clinical Rheumatology, 2017, 36, 317-326.	2.2	10
416	One year in review 2020: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology, 2020, 38, 181-194.	0.8	10
417	Criteria for the selection of single nucleotide polymorphisms in pathway pharmacogenetics: TNF inhibitors as a case study. Drug Discovery Today, 2009, 14, 837-844.	6.4	9
418	DCâ€induced CD8⁺ Tâ€cell response is inhibited by MHC class IIâ€dependent DX5⁺CD4⁺ Treg. European Journal of Immunology, 2009, 39, 1765-1773.	2.9	9
419	Role of rheumatology clinical nurse specialists in optimizing management of hand osteoarthritis during daily practice in secondary care: an observational study. Journal of Multidisciplinary Healthcare, 2011, 4, 403.	2.7	9
420	Human mast cells costimulate T cells through a CD28â€independent interaction. European Journal of Immunology, 2016, 46, 1132-1141.	2.9	9
421	Aesthetic dissatisfaction in patients with hand osteoarthritis and its impact on daily life. Scandinavian Journal of Rheumatology, 2016, 45, 219-223.	1.1	9
422	Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria. Rheumatology, 2019, 58, 730-732.	1.9	9
423	Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?. RMD Open, 2020, 6, e001242.	3.8	9
424	Earlier chronotype in patients with rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 2185-2192.	2.2	9
425	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. RMD Open, 2022, 8, e002079.	3.8	9
426	Analysis of allelic expression patterns of IL-2, IL-3, IL-4, and IL-13 in human CD4+ Tâ€„cell clones. European Journal of Immunology, 2003, 33, 2142-2148.	2.9	8
427	Quality indicators in rheumatology: valid for whom?. Annals of the Rheumatic Diseases, 2009, 68, 1797-1799.	0.9	8
428	Neutralization of IL-4 reverses the nonresponsiveness of CD4+ T cells to regulatory T-cell induction in non-responder mouse strains. Molecular Immunology, 2010, 48, 137-146.	2.2	8
429	Towards personalized treatment: predictors of short-term HAQ response in recent-onset active rheumatoid arthritis are different from predictors of rapid radiological progression. Scandinavian Journal of Rheumatology, 2012, 41, 15-19.	1.1	8
430	Brief Report: The Role of Rare Proteinâ€Coding Variants in Antiâ€“Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2017, 69, 735-741.	5.6	8
431	Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study. RMD Open, 2019, 5, e000840.	3.8	8
432	Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies. Annals of the Rheumatic Diseases, 2021, 80, 1124-1129.	0.9	8

#	Article	IF	Citations
433	Gene Therapy for the Treatment of Hip Prosthesis Loosening: Adverse Events in a Phase 1 Clinical Study. Human Gene Therapy, 2008, 19, 1029-1038.	2.7	7
434	Shared symptoms in rheumatic diseases: A blessing or a curse?. Arthritis and Rheumatism, 2009, 60, 2547-2549.	6.7	7
435	Auto-antibodies and cancer in systemic sclerosis. Autoimmunity Reviews, 2017, 16, 883-884.	5.8	7
436	Is current smoking status and its relationship to anti-cyclic citrullinated peptide antibodies a predictor of worse response to biological therapies in rheumatoid arthritis patients?. Scandinavian Journal of Rheumatology, 2018, 47, 360-363.	1.1	7
437	Comparison between low disease activity or DAS remission as treatment target in patients with early active rheumatoid arthritis. RMD Open, 2018, 4, e000649.	3.8	7
438	Phenotype and treatment of elderly onset compared with youngerâ€‚onset rheumatoid arthritis patients in international daily practice. Rheumatology, 2021, 60, 4801-4810.	1.9	7
439	Ten years of METEOR (an international rheumatoid arthritis registry): development, research opportunities and future perspectives. Clinical and Experimental Rheumatology, 2016, 34, S87-S90.	0.8	7
440	Translating basic research into clinical rheumatology. Best Practice and Research in Clinical Rheumatology, 2008, 22, 299-310.	3.3	6
441	Validity of the disease activity score in undifferentiated arthritis. Arthritis Care and Research, 2010, 62, 1392-1398.	3.4	6
442	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. Annals of the Rheumatic Diseases, 2011, 70, 1697-1698.	0.9	6
443	Pathway analysis to identify genetic variants associated with efficacy of adalimumab in rheumatoid arthritis. Pharmacogenomics, 2017, 18, 945-953.	1.3	6
444	Interpreting big-data analysis of retrospective observational data. Lancet Rheumatology, The, 2020, 2, e652-e653.	3.9	6
445	Association Between Centromere- and Topoisomerase-specific Immune Responses and the Degree of Microangiopathy in Systemic Sclerosis. Journal of Rheumatology, 2021, 48, 402-409.	2.0	6
446	Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus Science and Medicine, 2021, 8, e000472.	2.7	6
447	Seasonal variation of primary neuropsychiatric systemic lupus erythematosus. Journal of Rheumatology, 2006, 33, 1913-4; author reply 1914.	2.0	6
448	Fc gamma receptor binding profile of anti-citrullinated protein antibodies in immune complexes suggests a role for FcÎ³RI in the pathogenesis of synovial inflammation. Clinical and Experimental Rheumatology, 2018, 36, 284-293.	0.8	6
449	In rheumatoid arthritis patients, total IgA1 and IgA2 levels are elevated: implications for the mucosal origin hypothesis. Rheumatology, 2022, 62, 407-416.	1.9	6
450	DX5⁺CD4⁺ T cells modulate cytokine production by CD4⁺ T cells towards ILâ€‰10 via the production of ILâ€‰4. European Journal of Immunology, 2010, 40, 2731-2740.	2.9	5

#	Article	IF	Citations
451	Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Research and Therapy, 2014, 16, 430.	3.5	5
452	A prediction model for progressive disease in systemic sclerosis. RMD Open, 2015, 1, e000113.	3.8	5
453	Drivers of costly treatment strategies in rheumatoid arthritis. Lancet, The, 2016, 388, 213-214.	13.7	5
454	Illness perceptions, risk perceptions and worries in patients with early systemic sclerosis: A focus group study. Musculoskeletal Care, 2020, 18, 177-186.	1.4	5
455	Rheumatic?â€"A Digital Diagnostic Decision Support Tool for Individuals Suspecting Rheumatic Diseases: A Multicenter Pilot Validation Study. Frontiers in Medicine, 2022, 9, 774945.	2.6	5
456	5 Fc-gamma receptors: mediators, targets and markers of disease. Best Practice and Research: Clinical Haematology, 1991, 4, 889-902.	1.1	4
457	Genetics in rheumatoid arthritis. Current Rheumatology Reports, 2002, 4, 195-200.	4.7	4
458	Arthrography inÂloosened hip prostheses. Assessment ofÂpossibilities forÂintra-articular therapy. Joint Bone Spine, 2006, 73, 684-690.	1.6	4
459	Health care usage in Dutch systemic lupus erythematosus patients. Lupus, 2011, 20, 1147-1154.	1.6	4
460	<scp>DX</scp>5⁺<scp>CD</scp>4⁺<scp>T</scp> cells modulate <scp>CD</scp>4⁺<scp>T</scp>â€cell response via inhibition of <scp>IL</scp>â€12 production by <scp>DC</scp>s. European Journal of Immunology, 2013, 43, 439-446.	2.9	4
461	Autoimmunity: Break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Immunology Letters, 2014, 162, 150-162.	2.5	4
462	THU0114â€...Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. Annals of the Rheumatic Diseases, 2015, 74, 234.3-235.	0.9	4
463	Impact of pulmonary fibrosis and elevated pulmonary pressures on right ventricular function in patients with systemic sclerosis. Rheumatology, 2016, 55, kev342.	1.9	4
464	FRI0090â€...Analysis of neutrophils, lymphocytes, and platelets in pooled phase 2 and phase 3 studies of baricitinib for rheumatoid arthritis. , 2017, , .		4
465	Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy. Rheumatology, 2017, 56, 1721-1728.	1.9	4
466	On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis. Rheumatology International, 2018, 38, 2225-2231.	3.0	4
467	Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry. RMD Open, 2019, 5, e000969.	3.8	4
468	Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis. Clinical Rheumatology, 2020, 39, 1543-1549.	2.2	4

#	Article	IF	Citations
469	On using machine learning algorithms to define clinically meaningful patient subgroups. Annals of the Rheumatic Diseases, 2020, 79, e154-e154.	0.9	4
470	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. Arthritis Research and Therapy, 2020, 22, 85.	3.5	4
471	Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature. Arthritis Care and Research, 2021, 73, 722-731.	3.4	4
472	White matter hyperintensities associate with cognitive slowing in patients with systemic lupus erythematosus and neuropsychiatric symptoms. RMD Open, 2021, 7, e001650.	3.8	4
473	Profiling the Secretion of Soluble Mediators by End Stage Osteoarthritis Synovial Tissue Explants Reveals a Reduced Responsiveness to an Inflammatory Trigger. PLoS ONE, 2013, 8, e62634.	2.5	4
474	Suspected Transverse Myelitis with Normal MRI and CSF Findings in a Patient with Lupus: What to Do? A Case Series and Systematic Review. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 3173-3186.	2.2	4
475	A quantitative approach to early rheumatoid arthritis. Bulletin of the NYU Hospital for Joint Diseases, 2011, 69, 116-21.	0.7	4
476	To what extent do autoantibodies help to identify high-risk patients in systemic sclerosis?. Clinical and Experimental Rheumatology, 2018, 36 Suppl 113, 109-117.	0.8	4
477	ACPA-negative and ACPA-positive RA patients achieving disease resolution demonstrate distinct patterns of MRI-detected joint-inflammation. Rheumatology, 2022, 62, 124-134.	1.9	4
478	Fibroblast-like synoviocytes from rheumatoid arthritis patients express less FLICE-inhibitory protein than fibroblast-like synoviocytes from trauma patients: Comment on the article by Schedel et al. Arthritis and Rheumatism, 2003, 48, 858-859.	6.7	3
479	Genetics and clinical characteristics to predict rheumatoid arthritis: where are we now and what are the future prospects?. Future Rheumatology, 2006, 1, 79-89.	0.2	3
480	Early Rheumatoid Arthritis. Best Practice and Research in Clinical Rheumatology, 2009, 23, 1-2.	3.3	3
481	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Annals of the Rheumatic Diseases, 2011, 70, A1-A1.	0.9	3
482	The additive value of magnetic resonance imaging for bone edema in predicting rheumatoid arthritis development in early undifferentiated arthritis: Comment on the article by Duer-Jensen et al. Arthritis and Rheumatism, 2012, 64, 321-322.	6.7	3
483	Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 258.	3.5	3
484	Pharmacological conditioning in the treatment of recent-onset rheumatoid arthritis: a randomized controlled trial study protocol. Trials, 2020, 21, 15.	1.6	3
485	Body mass index and treatment survival in patients with RA starting treatment with TNFÎ±-inhibitors: long-term follow-up in the real-life METEOR registry. RMD Open, 2020, 6, e001203.	3.8	3
486	New risk model is able to identify patients with a low risk of progression in systemic sclerosis. RMD Open, 2021, 7, e001524.	3.8	3

#	Article	IF	Citations
487	A Polymorphism in C-C Chemokine Receptor 5 (CCR5) Associates with LÃ¶fgrenâ€™s Syndrome and Alters Receptor Expression as well as Functional Response. Cells, 2021, 10, 1967.	4.1	3
488	Longitudinal changes in cerebral white matter microstructure in newly diagnosed systemic lupus erythematosus patients. Rheumatology, 2021, 60, 2678-2687.	1.9	3
489	Management of contemporary early undifferentiated arthritis: data on EULARâ€™s recommendation on the risk of persistent disease. Annals of the Rheumatic Diseases, 2022, 81, 740-741.	0.9	3
490	Soluble FcgammaRIIIa as a marker for rheumatoid arthritis: the use of genetics in selected populations to study pathogenetic pathways. Journal of Rheumatology, 2003, 30, 1904-6.	2.0	3
491	N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?. Journal of Rheumatology, 2007, 34, 250-2.	2.0	3
492	MRI-Based Classification of Neuropsychiatric Systemic Lupus Erythematosus Patients With Self-Supervised Contrastive Learning. Frontiers in Neuroscience, 2022, 16, 695888.	2.8	3
493	Every shared epitope allele for itself?. Nature Reviews Rheumatology, 2009, 5, 477-478.	8.0	2
494	A7.1â€…A Genetic Variant in the Region ofMMP-9is Associated with Serum Levels and Progression of Joint Damage in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A48.1-A48.	0.9	2
495	A5.4â€…Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A31.2-A31.	0.9	2
496	A1.25â€…Visualisation and characterisation of citrullinated antigen-specific B cells from peripheral blood of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, A11.1-A11.	0.9	2
497	DAS steered therapy in clinical practice; cross-sectional results from the METEOR database. BMC Musculoskeletal Disorders, 2016, 17, 33.	1.9	2
498	Anti-cyclic citrullinated peptide antibodies, other common autoantibodies, and smoking as risk factors for lymphoma in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2018, 47, 270-275.	1.1	2
499	Treat-to-Target Strategies in Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 322, 83.	7.4	2
500	Quantitative susceptibility mapping in the thalamus and basal ganglia of systemic lupus erythematosus patients with neuropsychiatric complaints. NeuroImage: Clinical, 2021, 30, 102637.	2.7	2
501	Light chain skewing in autoantibodies and B-cell receptors of the citrullinated antigen-binding B-cell response in rheumatoid arthritis. PLoS ONE, 2021, 16, e0247847.	2.5	2
502	Cumulative endogenous estrogen exposure is not associated with severity of peripheral microangiopathy in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 82-87.	0.8	2
503	Smoking and systemic sclerosis: influence on microangiopathy and expression of anti-topoisomerase I antibodies in a monocentric cohort. Clinical and Experimental Rheumatology, 2020, 38 Suppl 125, 25-28.	0.8	2
504	Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology, 2022, , .	1.9	2

#	Article	IF	Citations
505	NT-proBNP and sRAGE levels in early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 243-249.	1.1	2
506	OUP accepted manuscript. Rheumatology, 2022, , .	1.9	2
507	Cytokine-Suppressive Anti-Inflammatory Drugs. BioDrugs, 1996, 6, 395-404.	0.7	1
508	Is the tuberculin skin test an accurate method of detecting tuberculosis in patients with rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2006, 2, 188-189.	3.2	1
509	The battle between anti-cyclic citrullinated peptide and rheumatoid factor testsâ€"a winner at last?. Nature Clinical Practice Rheumatology, 2007, 3, 696-697.	3.2	1
510	Which elements of the criteria for RA are stable over time?. Rheumatology, 2011, 50, 248-249.	1.9	1
511	Genetic interaction in the susceptibility of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A84-A84.	0.9	1
512	Genetic predisposition of the severity of joint destruction in rheumatoid arthritis; a population based study. Annals of the Rheumatic Diseases, 2012, 71, A56.2-A56.	0.9	1
513	Anticytomegalovirus seropositivity in rheumatoid arthritis is not associated with the presence of severe extraarticular complications: Comment on the article by Pierer et al. Arthritis and Rheumatism, 2012, 64, 2803-2804.	6.7	1
514	A7.10â€...Genetic Variants in theIL-4andIL-4Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts. Annals of the Rheumatic Diseases, 2013, 72, A51.2-A51.	0.9	1
515	A1.1â€...Anti-Citrullinated Protein Antibody Specific Fc Glycosylation Patterns in Arthralgia Patients. Annals of the Rheumatic Diseases, 2013, 72, A1.1-A1.	0.9	1
516	A1.8â€...Magnetic Resonance Imaging of Hand and Foot Joints of Patients with ACPA Positive Arthralgia without Clinical Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A3.3-A3.	0.9	1
517	A4.5â€...Do High Molecular Weight Adiponectin Levels Associate with Radiographic Progression in early Rheumatoid Arthritis and Hand Osteoarthritis?. Annals of the Rheumatic Diseases, 2013, 72, A25.1-A25.	0.9	1
518	87.â€ƒComparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis. Rheumatology, 2014, 53, i88-i89.	1.9	1
519	Is HLA-B27 Increased in Patients Diagnosed with Undifferentiated Arthritis? Results from the Leiden Early Arthritis Cohort. Journal of Rheumatology, 2014, 41, 1948-1951.	2.0	1
520	A1.28â€...Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. Annals of the Rheumatic Diseases, 2014, 73, A11.3-A12.	0.9	1
521	FRI0152â€...On Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 477.2-478.	0.9	1
522	AB0446â€...Treatment Effects and Minimal Clinically Important Differences in Patient-Reported Outcomes Following Treatment and Withdrawal of Abatacept, Methotrexate Or Combination Therapy in Patients with Early Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1044.1-1044.	0.9	1

#	Article	IF	Citations
523	Is optimising gout treatment the key to closing the mortality gap in gout patients?. Annals of the Rheumatic Diseases, 2018, 77, e2-e2.	0.9	1
524	PS7:129â€…Synergetic b-cell immunomodulation with rituximab and belimumab combination treatment in severe, refractory sle. , 2018, , .		1
525	Disruptive innovation in rheumatology: new networks of global publicâ€“private partnerships are needed to take advantage of scientific progress. Annals of the Rheumatic Diseases, 2020, 79, 553-555.	0.9	1
526	087â€ƒOn Drug and Drug-Free Remission by Baseline Disease Duration in the Avert Trial: Abatacept Versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis. Rheumatology, 0, , .	1.9	1
527	THU0024â€…Treatment with immune checkpoint inhibitors and the break of b-cell tolerance to autoantigens. , 2018, , .		1
528	Dissociation in SLE: A part of lupus fog?. Lupus, 2021, 30, 096120332110503.	1.6	1
529	Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry. Rheumatology International, 2022, , .	3.0	1
530	Vascular compromise of a finger due to tenosynovitis. Journal of Rheumatology, 2008, 35, 354.	2.0	1
531	No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years. Annals of the Rheumatic Diseases, 2022, 81, 1197-1199.	0.9	1
532	Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Human Genetics, 1996, 97, 813-818.	3.8	1
533	What will treatment of autoimmune diseases entail in 2010?. Seminars in Immunopathology, 2001, 23, 187-192.	4.0	0
534	Tweaking Microtubules to Treat Scleroderma. PLoS Medicine, 2005, 2, e415.	8.4	0
535	Pharmocogenetics in the future treatment of rheumatology. Future Rheumatology, 2007, 2, 337-339.	0.2	0
536	A european perspective on the 50th anniversary ofArthritis & Rheumatism. Arthritis and Rheumatism, 2008, 58, S136-S139.	6.7	0
537	State of the art lecture: IP53. Inflammatory Arthritis: Prospects for Next Decade. Rheumatology, 2011, 50, iii11-iii11.	1.9	0
538	Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. Annals of the Rheumatic Diseases, 2011, 70, A21-A21.	0.9	0
539	Fc-glycosylation of IgG1 is modulated by B cell Stimuli. Annals of the Rheumatic Diseases, 2011, 70, A61-A61.	0.9	0
540	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2011, 70, A5-A5.	0.9	0

#	Article	IF	Citations
541	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2012, 71, A52.1-A52.	0.9	0
542	Immunosuppressive DX5+ T cells are potent inhibitors of Th-1 responses via modulation of DCs. Annals of the Rheumatic Diseases, 2012, 71, A17.2-A18.	0.9	0
543	Pathogenic relevance of anti-citrullinated vimentin antibodies: Comment on the article by Montes et al. Arthritis and Rheumatism, 2013, 65, 541-542.	6.7	0
544	Editorial: Family Studies in the Information Age. Arthritis and Rheumatism, 2013, 65, 2762-2764.	6.7	0
545	Dr. Zirkzee, et al reply. Journal of Rheumatology, 2013, 40, 204.2-204.	2.0	0
546	A4.2â€...Adipocytes Modulate T Cell Function through Release of Lipids. Annals of the Rheumatic Diseases, 2013, 72, A24.1-A24.	0.9	0
547	OP0193â€...Motivations for seeking medical advice in arthralgia and early arthritis patients. Annals of the Rheumatic Diseases, 2013, 71, 120.1-120.	0.9	0
548	A10.21â€...Toll-Like Receptor Triggering of Human Basophils May Synergise with IgE-Mediated Activation in ACPA+ RA. Annals of the Rheumatic Diseases, 2013, 72, A79.2-A79.	0.9	0
549	OP0134â€...Risk stratification in patients with undifferentiated arthritis according to the 2010 ACR/EULAR criteria. Annals of the Rheumatic Diseases, 2013, 71, 98.3-99.	0.9	0
550	THU0020â€...Serum pyridinoline levels predict the severity of future joint destruction in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2013, 71, 160.2-160.	0.9	0
551	A5.29â€...Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A41.1-A41.	0.9	0
552	A4.3â€...Adipocytes Modulate the Phenotype of Macrophages through Secreted Lipids. Annals of the Rheumatic Diseases, 2013, 72, A24.2-A24.	0.9	0
553	OP0114â€...Improving early recognition of arthritis: Evaluation of the first year results on two early arthritis recognition clinics. Annals of the Rheumatic Diseases, 2013, 71, 91.3-92.	0.9	0
554	FRI0402â€...Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Annals of the Rheumatic Diseases, 2014, 73, 532.3-533.	0.9	0
555	A1.49â€...Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, A21.1-A21.	0.9	0
556	HLA-B60 and the HLA-B27/HLA-B60 genotype are not risk factors for acute anterior uveitis. Annals of the Rheumatic Diseases, 2014, 73, 633-634.	0.9	0
557	A1.29â€...In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinaged protein antibodies, but with the presence of several autoantibodies. Annals of the Rheumatic Diseases, 2014, 73, A12.1-A12.	0.9	0
558	FRI0186â€...Impact of Concomitant Methotrexate Dose on the Efficacy and Safety of Sarilumab for Treatment of Moderate-to-Severe Rheumatoid Arthritis: The Mobility Study. Annals of the Rheumatic Diseases, 2015, 74, 491.2-492.	0.9	0

#	Article	IF	Citations
559	Response to â€˜Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritisâ€™ â€“ authorsâ€™ reply. Arthritis Research and Therapy, 2015, 17, 171.	3.5	0
560	A7.4â€...The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. Annals of the Rheumatic Diseases, 2015, 74, A76.1-A76.	0.9	0
561	THU0040â€...In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 206.4-207.	0.9	0
562	A2.10â€...The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2016, 75, A19.1-A19.	0.9	0
563	A2.15â€...Ra phenotype at presentation differs among patients with few versus many autoantibodies. Annals of the Rheumatic Diseases, 2016, 75, A21.1-A21.	0.9	0
564	FRI0086â€...Before Clinically Detectable Arthritis Develops, ACPA-Positive and ACPA-Negative Arthralgia Patients Have Different Symptoms. Annals of the Rheumatic Diseases, 2016, 75, 458.1-458.	0.9	0
565	08.18â€...Anti-citrullinated protein antibodies: a marker of cardiovascular disease and mortality in patients without rheumatoid arthritis. , 2017, , .		0
566	05.11â€...Antisense long noncoding rnas are deregulated in skin tissue of ssc patients. , 2017, , .		0
567	AB0084â€...Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients. , 2017, , .		0
568	P5410Clinical and echocardiographic associates of all-cause mortality and cardiovascular outcomes in patients with systemic sclerosis. European Heart Journal, 2017, 38, .	2.2	0
569	P39â€...Longitudinal changes of cerebral white matter tissue microstructure in early-onset systemic lupus erythematosus. , 2020, , .		0
570	Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs. Annals of the Rheumatic Diseases, 2021, 80, 1364-1365.	0.9	0
571	OP0145â€...Gene-environment and disease interactions: is it smart to use cohort studies?. , 2001, , .		0
572	OP0313â€...Molecular analysis of anti-citrullinated protein antibody variable regions indicates aberrant selection processes during acpa b-cell development. , 2018, , .		0
573	Neuropsychiatric systemic lupus erythematosus is associated with a distinct type and shape of cerebral white matter hyperintensities. Rheumatology, 2021, , .	1.9	0
574	To treat or not to treat with immunosuppressive therapy: psychiatric disorders in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2022, 9, e000629.	2.7	0
575	Title is missing!. , 2020, 17, e1003296.		0
576	Title is missing!. , 2020, 17, e1003296.		0

#	Article	IF	Citations
577	Title is missing!. , 2020, 17, e1003296.		0
578	Title is missing!. , 2020, 17, e1003296.		0
579	Title is missing!. , 2020, 17, e1003296.		0
580	Title is missing!. , 2020, 17, e1003296.		0
581	Presence of SARS-CoV-2 antibodies in patients with COVID-19 like symptoms from the IENIMINI cohort. Scandinavian Journal of Rheumatology, 0, , 1-4.	1.1	0